相关实验视频

Updated: Jan 12, 2026

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption

Published on: July 30, 2016

印度药用植物在孕前管理中的潜在治疗用途

Sheema Wazib¹, Yashesvi Ambardar¹, Huma Quasimi¹

¹Department of Physiology, Hamdard Institute of Medical Sciences & Research, New Delhi, 110062, India.

Journal of Ayurveda and integrative medicine

|November 7, 2025

概括

印度药用植物通过向氧化应激和炎症等关键病理机制,显示出对治疗妊娠前的承诺. (Shatavari) 和其他植物可以改善孕产妇和胎儿的健康状况.

科学领域:

综合医学是一个整体的医学.
药理学药理学是指药理学的学科.
产科产科产科产科产科

背景情况:

孕前 (PE) 是一种严重的妊娠并发症,具有显著的孕产妇和胎儿风险.
目前的PE管理侧重于缓解症状和治疗,往往忽视了潜在的病理生理学.
印度药用植物通过准PE的核心机制,提供潜在的治疗益处.

研究的目的:

探索印度药用植物在治疗孕前的潜力.
研究这些植物如何解决PE中的氧化应激,炎症和内皮功能障碍.
为了突出阿斯巴拉古斯 racemosus (Shatavari) 作为一个关键的植物与相关的生物活性化合物.

主要方法:

审查有关印度药用植物药理性质的现有文献.
分析了诸如Hemidesmus indicus,Allium sativum,Tribulus terrestris,Curcuma longa,Withhania somnifera,Rheum officinale和Aspartus racemosus之类的植物的作用机制. 这些植物的作用机制包括:
专注于它们对氧化应激,炎症,氧化 (NO) 生物可用性和内皮功能的影响.

主要成果:

精选植物具有抗炎,抗氧化和内皮保护性质.
酸增强了氧化 (NO) 的生物可用性和血管扩张.
草 (Shatavari) 含有沙波宁,黄和抗氧化剂,可降低氧化应激并改善内皮功能.

结论:

印度药用植物通过准其病理生理学来提供一个有希望的,整体的方法来管理子宫前症.
(Shatavari) 和其他植物可以改善孕产妇和胎儿的健康状况.
需要进一步的严格研究来确认疗效,安全性和临床整合的最佳剂量.

关键词:

阿斯巴拉格斯是种类繁多的.脑内皮功能脑内皮功能印度药用植物印度药用植物氧化氧化是什么?孕前症孕前症氧化应激是一种氧化应激.

更多相关视频

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

A Plate-based Cytotoxicity Assay for the Assessment of Rat Placental Natural Killer Cell Cytolytic Function

A Plate-based Cytotoxicity Assay for the Assessment of Rat Placental Natural Killer Cell Cytolytic Function

Published on: June 2, 2019

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...

Mitral Valve Prolapse III: Nursing Management

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Pericarditis III: Medical Management

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...